IFP Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

IFP Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.86K	Buy	402 +6	+2%	+$81	﹤0.01%	3689
2026 Q1	$5K	Hold	396	–	–	﹤0.01%	3528
2025 Q4	$6.25K	Hold	396	–	–	﹤0.01%	3307
2025 Q3	$4.74K	Buy	396 +11	+3%	+$88	﹤0.01%	3286
2025 Q2	$3.08K	Buy	+385	New	+$2.32K	﹤0.01%	3683
2025 Q1	–	Sell	-3	Closed	-$17	–	4402
2024 Q4	$17	Buy	+3	New	+$29	﹤0.01%	4475
2020 Q4	–	Sell	-259	Closed	-$11.4K	–	2987
2020 Q3	$11K	Buy	+259	New	+$12.5K	﹤0.01%	1864
2018 Q4	–	Sell	-136	Closed	-$12K	–	3615
2018 Q3	$12K	Hold	136	–	–	﹤0.01%	2739
2018 Q2	$16K	Hold	136	–	–	﹤0.01%	2597
2018 Q1	$8K	Hold	136	–	–	﹤0.01%	2912
2017 Q4	$8K	Hold	136	–	–	﹤0.01%	2957
2017 Q3	$6K	Hold	136	–	–	﹤0.01%	3291
2017 Q2	$5K	Hold	136	–	–	﹤0.01%	3383
2017 Q1	$4K	Sell	136 -175	-56%	-$5.45K	﹤0.01%	3400
2016 Q4	$10K	Buy	311 +136	+78%	+$3.9K	﹤0.01%	2889
2016 Q3	$5K	Sell	175 -1,476	-89%	-$34.3K	﹤0.01%	3215
2016 Q2	$36K	Buy	+1,651	New	+$43.2K	﹤0.01%	1966
2016 Q1	–	Sell	-1,714	Closed	-$57K	–	2654
2015 Q4	$57K	Buy	+1,714	New	+$55.9K	﹤0.01%	1524

Other funds holding ENTA

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KAM

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

IFP Advisors's ENTA Position: Q2 2026 in Review

IFP Advisors increased its Enanta Pharmaceuticals (ENTA) stake by 1.5% in Q2 2026, buying an estimated $81 and bringing the position to 402 shares worth $5.86K. The position accounts for ﹤0.01% of the portfolio, ranked #3689.

IFP Advisors first reported a position in ENTA in Q4 2015 and has held it in 18 quarters since. The position peaked at $57K in Q4 2015. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

IFP Advisors held 402 shares of Enanta Pharmaceuticals worth $5.86K as of Q2 2026.
IFP Advisors bought 6 Enanta Pharmaceuticals shares in Q2 2026, an estimated $81.
Enanta Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3689 holding.
IFP Advisors first reported a position in Enanta Pharmaceuticals in Q4 2015 and has held it in 18 quarters since.
IFP Advisors's Enanta Pharmaceuticals position peaked at $57K in Q4 2015.
123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.